<DOC>
	<DOCNO>NCT01996046</DOCNO>
	<brief_summary>This study evaluate baseline uptake FDG PET/CT scan patient breast cancer spread bone . A repeat FDG PET/CT scan do 4 week start new breast cancer hormone treatment 12 week treatment start . The baseline uptake change uptake repeat scan compare clinical long term outcome time progression overall survival . In addition uptake compare incidence skeletal related event common occurrence patient cancer spread bone .</brief_summary>
	<brief_title>FDG PET/CT Breast Cancer Bone Mets</brief_title>
	<detailed_description>This observational study patient receive research diagnostic test , FDG PET/CT study perform 4 week start new hormone treatment .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Adult patient , least 18 year age , history pathologically confirm ER+ breast cancer 2 . Biopsy proven clinically obvious document bone metastasis breast cancer ( majority disease burden bone ) 3 . Patients plan start new endocrine target therapy ( line therapy acceptable endocrine therapy allow ) 4 . Willing able comply schedule visit serial imaging procedure 5 . Agrees allow access clinical record regard response treatment long term follow . 6 . Be inform investigational nature study provide write informed consent accordance institutional federal guideline 1 . Women pregnant breast feed 2 . Uncontrolled diabetes mellitus ( fast glucose great 200 mg/dL ) 3 . Inability tolerate imaging procedure ( e.g . claustrophobia , severe pain ) 4 . Weight exceed capacity image table 5 . Previous treatment radiation surgery significant percentage bony metastatic site 6 . Treatment marrow stimulate agent ( e.g . granulocyte colony stimulate factor ( GCSF ) ) within 3 week baseline scan</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>